Allergy & Asthma Network has been at the forefront of pivotal conversations with Mylan for over six months regarding this matter, speaking out and standing up for families that have been affected. While the Network is continuing these conversations and advocating for patients each day, it is also providing patients with resources to lower the price, such as discount coupons and decoding health insurance plans to minimize out-of-pocket costs.

The Network has followed, tracked, and published papers over the past four years discussing the cost shifting of healthcare to patients. The Network has spoken out regarding the EpiPen price increase in over 100 media outlets, including The New York Times and, addressing our concerns for families with high deductible health insurance plans who are now unable to afford this life-saving medication from Mylan.

The goal is to get all epinephrine auto-injectors placed on Preventive Drug Lists of government and commercial insurance plans to help eliminate out-of-pocket expenses for families, as well as ensure access to life-saving medications for all.